In melanoma and lung and prostate tumors, targeting recruitment of MDSCs by inhibiting CSF-1 receptor inhibits tumor angiogenesis associated with reduced expression of proangiogenic genes such as VEGF-A and MMP-9 and reverses tumor resistance to antiangiogenic therapy (57). This evidence concerns the gene MMP9 and neoplasm.